Sanson et al. highlighted that the IDH1 codon 132 mutation is associated with the genomic profile of the tumor and constitutes an independent prognostic marker in G II to IV gliomas (p = 0.00021) [66]. This evidence concerns the gene IDH1 and central nervous system cancer.